This video brief features Dr. Matthew Budoff reporting from AHA 2025 in New Orleans. He presents findings from the VESALIUS-REAL Global Burden Study, which assessed the incidence of stroke and myocardial infarction across diverse regions in patients at high risk of a first major atherosclerotic cardiovascular event (MACE). Dr. Budoff reviews the study’s design and geographic scope and offers insights into the global burden of atherosclerotic events in individuals without prior cardiovascular disease. He also highlights the clinical implications of these findings for guiding primary cardiovascular prevention strategies across varied populations.
Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study

Transcript
Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
closeReady to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Provider(s)/Educational Partner(s)

Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.Commercial Support
This activity is supported by an independent educational grant from Amgen, Inc.
videoEvolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial
Show more
videoReal-World Impact of Evolocumab on MACE Reduction in ASCVD
Show more
videoPrimary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
Show more
Overview
This video brief features Dr. Matthew Budoff reporting from AHA 2025 in New Orleans. He presents findings from the VESALIUS-REAL Global Burden Study, which assessed the incidence of stroke and myocardial infarction across diverse regions in patients at high risk of a first major atherosclerotic cardiovascular event (MACE). Dr. Budoff reviews the study’s design and geographic scope and offers insights into the global burden of atherosclerotic events in individuals without prior cardiovascular disease. He also highlights the clinical implications of these findings for guiding primary cardiovascular prevention strategies across varied populations.
Provider(s)/Educational Partner(s)

Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.Commercial Support
This activity is supported by an independent educational grant from Amgen, Inc.
videoEvolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial
Show more
videoReal-World Impact of Evolocumab on MACE Reduction in ASCVD
Show more
videoPrimary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
Show more
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?



